Molecular Basis of Apolipoprotein(a) Isoform Size Heterogeneity as Revealed by Pulsed-Field Gel Electrophoresis

This genetic study used pulsed-field gel electrophoresis to map the apo(a) gene size polymorphism at the genomic level — directly measuring the variable kringle IV repeat sequences that determine apo(a) protein size and plasma Lp(a) concentration.

Nineteen distinct alleles were identified; 94 percent of individuals were heterozygous, with allele sizes varying from 48 to 190 kilobases. The critical findings: apo(a) gene size correlated directly with protein size and inversely with plasma Lp(a) concentration, and siblings with the same apo(a) genotype had remarkably similar Lp(a) levels. Genetics explained what population epidemiology had long suggested — that Lp(a) concentration is essentially determined at birth.

This genetic architecture has profound clinical consequences. Since Lp(a) is genetically fixed and largely unresponsive to diet, exercise, or conventional lipid-lowering drugs, an elevated Lp(a) represents a lifelong inherited risk — not a modifiable one in the traditional sense. This is the fundamental rationale for dedicated Lp(a)-lowering RNA therapeutics now in late-stage development.

We rate the evidence strong. A landmark molecular genetics study establishing the heritable, gene-level basis of Lp(a) variation — foundational to the contemporary understanding of Lp(a) as a causal, inherited cardiovascular risk factor requiring dedicated therapeutic targeting.